JPMorgan downgrades Leidos stock rating on margin concerns
JPMorgan downgraded Leidos (LDOS) to Neutral from Overweight, cutting its price target to $142 from $160. The firm expects 1-2% organic growth in 2027 but forecasts a decline in the Health segment's margins. Leidos reported Q2 2026 earnings and revenue above estimates, raising its full-year guidance. Analysts cite concerns about the Health segment and VA contract rebid.
How this was made
The 30-second read
Why it matters
The downgrade may trigger short‑term selling, but the company's recent earnings beat and new defense contract provide a counterbalance.
Market read
Analyst rating change is a fresh catalyst that can move LDOS shares in the near term.
What to watch
The $85 million Department of War contract and strong defense product outlook could offset margin worries.
Background
JPMorgan analysts lowered their outlook on Leidos after noting a decline in adjusted EBITDA margins, especially in the Health segment.
Ticker impact
JPMorgan downgraded Leidos Holdings to Neutral and cut its price target to $142, citing margin pressure.
likely downward pressure as investors price in weaker margins
The downgrade reflects concerns over shrinking EBITDA margins, which typically prompts short‑term sell pressure.
Market effects
Defense and aerospace peers may see modest spillover as margin concerns raise questions about the sector.
U.S. defense stocks could face slight pressure.
Limited to U.S. equities; no broader macro impact.
Counterpoint
Some investors may view the downgrade as an overreaction given Leidos' recent earnings beat and contract win.
Key entities
- companyLeidos Holdings
U.S. defense and health technology contractor
- analyst_firmJPMorgan
Issued the downgrade and new price target
